Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

113.13 +4.90 (+4.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
65 66 Next >
If You Invested $1,000 In BioNTech Stock At Its Pandemic Low, Here's How Much You'd Have Now
Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than... 
Via Benzinga
Novavax Stock Could Give Back More of Its Pandemic-Era Gains
While trading at a very low multiple to the low end of earnings estimates, NVAX stock may still be trading at a premium. 
Via InvestorPlace
Public-health Authorities in US, UK, Probe Mysterious Cases Of Severe Hepatitis In Young Kids: WSJ
Via Benzinga
Pfizer: What Comes After the Covid-19 Fire?
Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles. 
Via InvestorPlace
7 Top-Rated Biotech Stocks to Buy for Q2
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. 
Via InvestorPlace
Expert Ratings for BioNTech
Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings: 
Via Benzinga
4 Undervalued Biotech Stocks to Add to Your Buy List
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
Via InvestorPlace
UK-Based Start-Up Working On Next COVID-19 Vaccine Using Animal Feces: FT
Via Benzinga
Pfizer/BioNTech Fourth COVID-19 Vaccine Dose Protects Against Omicron For At Least One Month
A fourth dose of the COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) provided significant protection against severe disease, hospitalization, and death for at least a month... 
Via Benzinga
AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt
Key takeaways: Vaccine maker AIM has filed for an IPO in Hong Kong, following unsuccessful previous bids in Hong Kong and on Shenzhen’s ChiNext board The company has three Covid vaccines under... 
Via Benzinga
Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report
Via Benzinga
As Evolving Pandemic Response, Officials Shift To Personal Choice On COVID-19 Boosters, Masks: WSJ
In the latest phase of the COVID-19 pandemic, federal and local officials are leaving it up to people to assess if they need booster shots, whether to wear a mask and how long to isolate after a... 
Via Benzinga
Novavax: The Party’s Over
Novavax was a great speculation on hopes for its Covid-19 vaccine, but now that the virus is becoming endemic, sentiment is waning. 
Via InvestorPlace
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Healthcare Stocks Finding Buyers Again, MRNA, VERU, BNTX
It seems like buying interests are coming back to COVID-19 stocks. 
Via Talk Markets
Pfizer/BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Aged 5-11 Years
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from a Phase 2/3 trial of a 10 µg booster (third) dose of COVID-19 vaccine in children aged 5-11 years. 
Via Benzinga
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
HC Wainwright Reiterates Buy Rating On BioNTech, While Lowers Price Target
HC Wainwright has reiterated its Buy rating on BioNTech SE (NASDAQ: BNTX) while reducing the price tar 
Via Benzinga
Covid Proved Their Tech, But Moderna, BioNTech Face A New Battle
Demand for Covid boosters is low. What's next for the formerly red-hot vaccine stocks? 
Via Investor's Business Daily
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
BioNTech Posts Interim Phase 1 Data From CAR-T/Cancer Vaccine Combo In Solid Tumors
BioNTech SE (NASDAQ: BNTX) presented data from its ongoing Phase 1/2 trial of its CAR-T cell therapy candidate, BNT211, in advanced solid tumors.  
Via Benzinga
Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech
BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have  
Via Benzinga
Friday Stocks Update
Royal Dutch Shell rose again on its earnings but is still at a p/e ratio of under 11x earnings. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Market Rally Falters As Hawkish Fed Slams Techs; Musk Buys Twitter Stake, Holds Tesla 'Rodeo': Weekly Review
A hawkish Fed hit the major indexes. Tesla CEO Elon Musk bought a big Twitter stake. 
Via Investor's Business Daily
Europe Holds Second COVID-19 Booster Dose For People Aged Under 80 Years
European Medicines Agency concluded that it is too early to consider using the fourth dose of either Pfizer Inc (NYSE: 
Via Benzinga
FDA Official Says Frequent COVID-19 Booster Shows Not Sustainable: WSJ
According to a U.S. health regulator, asking people to get COVID-19 boosters frequently wasn't sustainable because of vaccine fatigue, and authorities needed to develop a long-term strategy for... 
Via Benzinga
Pfizer/BioNTech's Second COVID-19 Vaccine Booster Provides Short-Lived Protection In Elderly, Israel Study Shows
An Israel-based study has found that a fourth dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) vaccine lowered rates of COVID-19 infection among the elderly. 
Via Benzinga
Moderna, BioNTech Dive As Israel Study Looks Bearish On Fourth Covid Shot
Vaccine stocks toppled Wednesday after an Israeli study suggested immunity wanes quickly following a second Covid booster shot. 
Via Investor's Business Daily
Morning Brief: Top Stories Dominating Financial Media on Tuesday, April 5
CNBC Former DeepMind Officials Get Together To Develop AI For Stock and Crypto Picking Martin Schmid, Rudolf Kadlec, and Matej Moravcik left Alphabet Inc (NASDAQ: GOOG) (NASDAQ:... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.